[HTML][HTML] A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of …
V Backer, U Sjöbring, J Sonne, A Weiss… - The Lancet Regional …, 2021 - thelancet.com
Background Coronavirus disease 19 (COVID-19) is spreading globally and treatment
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19
V Backer, U Sjöbring, J Sonne, A Weiss… - The Lancet regional …, 2021 - research.regionh.dk
Background: Coronavirus disease 19 (COVID-19) is spreading globally and treatment
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19
V Backer, U Sjöbring, J Sonne… - The Lancet …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Coronavirus disease 19 (COVID-19) is spreading globally and treatment
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19 …
nexs.ku.dk
Background: Coronavirus disease 19 (COVID-19) is spreading globally and treatment
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19
V Backer, U Sjöbring, J Sonne, A Weiss… - Lancet Regional Health …, 2021 - orbit.dtu.dk
Abstract Coronavirus disease 19 (COVID-19) is spreading globally and treatment options
remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a broad …
remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a broad …
[HTML][HTML] A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of …
V Backer, U Sjöbring, J Sonne, A Weiss… - The Lancet Regional …, 2021 - Elsevier
Background Coronavirus disease 19 (COVID-19) is spreading globally and treatment
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
[HTML][HTML] A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of …
V Backer, U Sjöbring, J Sonne, A Weiss… - The Lancet Regional …, 2021 - ncbi.nlm.nih.gov
Background Coronavirus disease 19 (COVID-19) is spreading globally and treatment
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19
V Backer, U Sjöbring, J Sonne, A Weiss, M Hostrup… - ikm.ku.dk
Background: Coronavirus disease 19 (COVID-19) is spreading globally and treatment
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19.
V Backer, U Sjöbring, J Sonne, A Weiss… - The Lancet Regional …, 2021 - europepmc.org
Background Coronavirus disease 19 (COVID-19) is spreading globally and treatment
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19.
V Backer, U Sjöbring, J Sonne, A Weiss… - The Lancet Regional …, 2021 - europepmc.org
Background Coronavirus disease 19 (COVID-19) is spreading globally and treatment
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …
options remain limited. A formulation of niclosamide, a potent anti-SARS-CoV-2 agent and a …